RecruitingPhase 1NCT06702488

Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics

The Efficacy of Dexmedetomidine and Magnesium Sulfate in Cognitive Dysfunction


Sponsor

Fayoum University

Enrollment

58 participants

Start Date

Nov 21, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Magnesium sulfate is considered a neuroprotective drug and has been studied in various applications. Recently, it has drawn the attention of anesthesiologists, resulting in numerous publications about its role in anesthesiology. Magnesium sulfate is suggested to exert its neuroprotective effect by preventing excitotoxicity. in the clinical setting, intraoperative magnesium sulfate attenuated POCD. Furthermore, postoperative emergence agitation was significantly reduced in pediatric patients who received intraoperative magnesium sulfate during adenotonsillectomy. The aim of this study The aim of this work is to compare the protective effect of intraoperative dexmedetomidine with magnesium sulfate against developing POCD and to study their effect on serum level of CRP; the marker of neuronal degeneration.


Eligibility

Min Age: 60 YearsMax Age: 80 Years

Inclusion Criteria2

  • ASA physical status I, II and ⅠⅠⅠ
  • patients undergoing open abdominal surgery under general anesthesia

Exclusion Criteria3

  • Elderly patients with preoperative MoCA Score below 26.
  • Operation time more than 4 hours to prevent excessive dosage of magnesium sulfate.
  • BMI > 35 kg m-2

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdexmedetomidine

20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.


Locations(1)

Dexmedetomidine

Al Fayyum, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06702488


Related Trials